Study design
Study will be a pilot longitudinal prospective study. SLK transplant listed patients will
be recruited from the outpatient Liver Kidney Transplant Clinic at Medical Diagnostic
Clinic (MDC) as well as inpatients admitted to IU University Hospital. Listing status for
SLK transplant will be confirmed and patients will be scheduled for a Mag3 nuclear
medicine scan at IU University Department of Nuclear medicine. For study purposes, this
scan will be done pre and post-transplant to compare the results.
Methods:
Inclusion/Exclusion criteria:
Inclusion:
> 18 years old
Listed for Liver Transplant for ESLD and Kidney Transplant based on eGFR ranging
from ≥ 25 to ≤40 mL/min/1.73m2 (not on dialysis at time of surgery)
Candidates with two native kidneys.
Willing to participate and sign informed consent form.
Exclusion Criteria:
Unstable patients (e.g. in the ICU or those who are on Continous Renal Replacement
Therapy (CRRT) who cannot complete the nuclear medicine scan or those on
Hemodialysis
Prior history of any solid organ transplant.
Those who are currently pregnant or breast feeding.
Patients with a history of Adult Polycystic Kidney Disease
Data collection: Data collection will be done in RedCap©️ These data forms will
incorporate a comprehensive list of variables:
Participants demographics and BMI
Reason for ESLD and complications listed in Medical Chart
Medication list
Results of Nuclear medicine scan, eGFR on Basic Metabolic Panel, measurement of eGFR
by Cystatin C, 24 hour urinary creatinine clearance and measurement of urinary NGAL
level. Radiographically: kidney size, presence of findings such as cysts, stones
etc.
Post SLK transplant complications including need for Dialysis, delayed graft
function, episodes of rejection, infections and any reason for admission to the
hospital
Adherent to Immunosuppression regimen, and type of Immunosuppression regimen
BP readings at follow up clinic visits
Any post SLK transplant imaging for kidney size and any findings (if any imaging is
performed for any other indication, none will done for the research study).
Participants will be informed about the results of their studies. Participation will be
voluntary. Compensation will be provided once in the form of $25 gift card that will be
provided upon completing participation for the nuclear medicine scan 10 months after
patients receive their SLK transplant. Patients and their insurance will not be charged
and the testing will be invoiced to the study grant.
Provisions for post-study care No provision will be provided for care regarding
incidental findings on the nuclear medicine scan. They will be given information
regarding referral to seeking appropriate care. No expenses will be reimbursed for this
care.
Participant timeline:
Enrollment of participants will be done starting February 2023 and completed by December
2023
Statistical Analyses:
Sample size:
Estimated number of participants is determined by participants listed for SLK transplant.
An estimated 15 participants are planned to be recruited. As this is a pilot study, all
participants at IU will be asked to participate with a future goal of a multi-center
study.
Plans for assessment and collection of outcomes:
Data will be collected in IU RedCap registry, which is a secure platform. Data will be
entered in Redcap, coded, secured, and stored. Any raw data collection (source documents)
will be kept in a locked cabinet in a locked office. Data will be processed with SPSS
data management software.
Confidentiality Information about potential and enrolled participants will be collected,
shared, and maintained in a manner that protects confidentiality before, during, and
after the study.